EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System

Guojun Liang iD, Xiaofang Liu, Mengge Gao, Bo Yang, Yang Song, Qiong Liu iD

Pharmacology Research & Perspectives · 2025

DOI: 10.1002/prp2.70194 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Guojun Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Huadu District People's Hospital of Guangzhou, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Adverse Drug Reaction Reporting Systems, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Avacopan, an oral C5a receptor antagonist approved for treating anti‐neutrophil cytoplasmic antibodies (ANCA) associated vasculitis, has established efficacy and short‐term safety from clinical trials, but its post‐marketing adverse events (AEs) in real‐world settings require further characterization. We conducted a retrospective analysis of the U.S. FDA Adverse Event Reporting System (FAERS) database from Q1 2022 to Q1 2025. After data cleaning, Avacopan‐related AEs were extracted, coded using MedDRA terminology, and analyzed via four signal detection methods; subgroup analyses by age, sex, and reporter type were performed. Among 3529 reports, significant disproportionality signals emerged for known AEs (e.g., hepatobiliary disorders, serious infections) and unexpected signals including venous thromboembolism, cholestatic jaundice, and alopecia. Most AEs occurred within the first 30 days of treatment, with variations observed by age and sex. This study provides the first FAERS‐based pharmacovigilance assessment of Avacopan, confirming known risks and identifying novel post‐approval safety signals, underscoring the need for close early‐treatment monitoring and personalized strategies. Further research is warranted to confirm emerging signals and explore their mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adverse Drug Reaction Reporting SystemsAnti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHumansUnited StatesMaleFemaleUnited States Food and Drug AdministrationRetrospective StudiesMiddle AgedAdultAgedPharmacovigilanceAdolescentYoung AdultChildAged, 80 and overChild, Preschool

Stichwörter der Autor:innen

FAERSavacopandisproportionality analysispharmacovigilancepost‐marketing safety

Autor:innen und Institutionen

  • Huadu District People's Hospital of Guangzhou, Guangzhou, Guangdong, China.

ORCID-Profile: Guojun Liang, Qiong Liu

Zitieren

APA

Liang, G., Liu, X., Gao, M., Yang, B., Song, Y., & Liu, Q. (2025). A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70194

Vancouver

Liang G, Liu X, Gao M, Yang B, Song Y, Liu Q. A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70194

BibTeX
@article{Liang2025,
  author = {Liang, Guojun and Liu, Xiaofang and Gao, Mengge and Yang, Bo and Song, Yang and Liu, Qiong},
  title = {A Real‐World Disproportionality Analysis of Avacopan in Anti‐Neutrophil Cytoplasmic Antibodies Associated Vasculitis: Insights From FDA Adverse Event Reporting System},
  journal = {Pharmacology Research & Perspectives},
  year = {2025},
  doi = {10.1002/prp2.70194}
}
Kostenlos starten →